Internal benchmarks from the company show that the new technology, to be released next month, predicts variant pathogenicity with 98 percent accuracy.
The company was established earlier this year by the co-founders of reproductive genetics firm Recombine, which was sold to CooperSurgical in May.
BC Platforms will work with the personalized medicine firm to create a large-scale biobank of genetic and phenotypic data samples from Mexican individuals.
The Office of the National Coordinator for Health Information Technology's ability to test new standards and policies is hindered without $5 million Obama requested for FY2016.
Researchers designed software for the MinIon that enables targeted sequencing without target capture or enrichment.
In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.
At Nature, John Wilbanks and Eric Topol call for openness in health data.
Law.com predicts that genomic and genetic testing will become common in toxic tort cases.
A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.